RWP
NGNE icon

RWA Wealth Partners’s Neurogene NGNE Stock Holding History

RWA Wealth Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,691
Closed -$34K – 269
2022
Q3 		$34K Sell
2,691
-579
-18% -$11.8K ﹤0.01% 241
2022
Q2 		$67K Buy
3,270
+929
+40% +$22.7K ﹤0.01% 238
2022
Q1 		$88K Buy
2,341
+1,818
+348% +$106K 0.01% 251
2021
Q4 		$50K Buy
+523
New +$63.7K ﹤0.01% 246

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RWA Wealth Partners's NGNE Position: Q4 2022 in Review

RWA Wealth Partners sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 2,691 shares — an estimated $34K sold.

RWA Wealth Partners first reported a position in NGNE in Q4 2021 and held it in 4 quarters. The position peaked at $88K in Q1 2022. 45 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

  • RWA Wealth Partners reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
  • RWA Wealth Partners sold 2,691 Neurogene shares in Q4 2022, an estimated $34K.
  • RWA Wealth Partners first reported a position in Neurogene in Q4 2021 and held it in 4 quarters.
  • RWA Wealth Partners's Neurogene position peaked at $88K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on RWA Wealth Partners's 13F filing for Q4 2022, filed 19 Jan 2023.